Cancer Immunotherapy Related Endocrine Adverse Effects
International Journal of Thyroidology
;
: 97-104, 2019.
Article
in Korean
| WPRIM
| ID: wpr-785842
ABSTRACT
Cancer immunotherapy has emerged as a promising therapy for a wide variety of tumors. Immune checkpoint inhibitors including anti cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1) monoclonal antibodies have proven to be especially effective in various advanced cancers. However, cancer the immunotherapy disturbs the immune system and may also cause immune related side effects (IRAE) distinguished from cytotoxic chemotherapy toxicity. Among them, endocrine IRAE has been reported with a higher incidence than other organ IRAE. We focus on the most relevant and new aspects related to endocrine IRAE due to cancer immunotherapy in this review.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Incidence
/
Drug Therapy
/
CTLA-4 Antigen
/
Immune System
/
Immunotherapy
/
Antibodies, Monoclonal
Type of study:
Incidence study
/
Prognostic study
Language:
Korean
Journal:
International Journal of Thyroidology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS